abstract |
The present invention relates to FUBP1 inhibitors for use in the treatment of HBV infections, particularly chronic HBV infections. In particular, the present invention relates to the use of FUBP1 inhibitors to destabilize cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules such as oligonucleotides, including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing FUBP1 mRNA. Also included in the present invention are pharmaceutical compositions and their use in the treatment and/or prevention of HBV infection. |